Home > Boards > US Listed > Medical - Drugs >

Avadel Pharmaceuticals (ADVL)

Add ADVL Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 2/10/2021 4:04:10 PM - Followers: 1 - Board type: Free - Posts Today: 0

Flamel Technologies Completes Cross-Border Merger and Becomes Avadel Pharmaceuticals plc GlobeNewswire•January 3, 2017 DUBLIN, Ireland, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Flamel Technologies SA, completed its previously announced cross-border merger with and into its wholly-owned Irish subsidiary, Avadel Pharmaceuticals plc (NASDAQ:AVDL) (Avadel), effective January 1, 2017, with Avadel surviving the merger as the public holding company. As a result of the merger, all of Flamel’s outstanding ordinary and American Depository Shares (ADSs) were canceled and exchanged on a one-for-one basis for Avadel ordinary shares and ADSs, respectively. Avadel ADSs will begin trading on the NASDAQ Global Market under trading symbol “AVDL” on January 3, 2017. Michael Anderson, Avadel’s Chief Executive Officer, remarked, “We are excited to enter 2017 as Avadel. The completion of the cross-border merger from France to Ireland serves as a way to unify our subsidiaries under a shared corporate identity, and provides the company with a new set of corporate governance policies that will allow us greater flexibility as we continue to grow our business and commercialize products.” Mr. Anderson continued, “Our new name, Avadel, which stands for ‘advanced delivery,’ was born out of our company’s strong history in drug delivery and serves as a constant reminder of a key piece of our company’s growth strategy – to develop differentiated pharmaceutical products utilizing our proprietary and innovative technologies.” “We are excited to begin 2017 with a new name, an ongoing Phase III trial and a strong financial position,” finished Mr. Anderson. About Avadel Pharmaceuticals plc: Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results. Avadel currently markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#15   good article on S A Paullee 02/10/21 04:04:10 PM
#14   Avadel Pharmaceuticals Announces Submission of New Drug Application Paullee 12/16/20 08:29:18 AM
#13   Paullee 11/17/20 05:15:12 AM
#12   Kid looks like he is about 18 but Paullee 09/30/20 07:36:30 AM
#11   Into the homestretch Paullee 04/27/20 07:52:37 AM
#10   Avadel Pharmaceuticals Completes the REST-ON Phase 3 Pivotal Paullee 03/25/20 08:08:08 AM
#9   Avadel Pharmaceuticals Receives U.S. FDA Approval for Nouress™ Paullee 12/16/19 08:06:46 AM
#8   Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase Paullee 11/25/19 08:11:28 AM
#7   Drugmaker Avadel Gets Boost From Parent In Del. Paullee 02/11/19 06:38:15 AM
#6   Drugmaker Files Ch. 11, Blames Low-Selling Urination Drug Paullee 02/11/19 06:37:55 AM
#5   Avadel Launches NOCTIVA™, the First and Only FDA-Approved Paullee 05/01/18 10:04:35 AM
#4   Avadel Pharmaceuticals Announces Divestiture of Pediatric Business Paullee 02/12/18 09:18:39 AM
#3   Local press Paullee 02/09/18 11:25:36 PM
#2   Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA Paullee 01/10/18 07:55:06 AM
#1   https://finance.yahoo.com/news/top-cheap-stocks-week-130223440.html Avadel Phar Paullee 12/16/17 01:34:24 PM
Consent Preferences